by Robert J. Pizzutiello, Jr MS
The ideal change process for digital mammography relies on an informed multidisciplinary team that conducts a rigorous technology assessment.
Robert J. Pizzutiello, Jr, MS
|
Although
most imaging providers considering the acquisition of a new
technology conduct some kind of evaluation, their assessment
process may be less than adequate unless it involves the
radiologists, technologists, information specialists, and office
staff who will provide the proposed new service. Without the input
and expertise of those in the best position to assess the impact of
a new technology, any evaluation of its probable value may be less
comprehensive and, ultimately, less helpful.
Facilities investigating conversion from screen-film mammography
(SFM) to full-field digital mammography (FFDM) can benefit greatly
from a team approach to technology assessment, not only because the
breadth of available knowledge will make the evaluation more
reliable, but because the teamwork involved in preparing a thorough
assessment can carry over into the project's implementation phase,
enhancing the ultimate chances of success. In itself, the act of
reaching consensus by considering several perspectives
simultaneously can increase the team's commitment to the project's
success.
TEAM COMPOSITION
A multidisciplinary team should be assembled to evaluate the
prospect of changing from SFM to FFDM. Whether the facility is a
practice devoted solely to breast imaging or is part of a larger
freestanding imaging center or hospital radiology department, the
first step in technology assessment is the creation of a team
having the broadest possible expertise.
The team should include one or more radiologists, whose role
will be to evaluate the clinical impact of FFDM and its probable
effects on workflow. A mammography technologist holding a
supervisory or senior post will be responsible, as a member of the
team, for tracking patient movement through a hypothetical FFDM
visit. The technologist will also assess any FFDM-related changes
in workflow and technologists' duties that can be expected.
The team's medical physicist will be responsible for the
evaluation of the available FFDM technologies, with particular
emphasis on image-receptor types, image quality, and radiation
dose. The optimal arrangement of film and digital image viewers may
also be the responsibility of this team member. It will be
especially important to keep ambient light low and to reduce glare.
The room's layout may need especially careful attention since both
conventional filmboxes and computers other than those used to
interpret FFDM images may very likely be used in the same
space.
An information-technology specialist should be part of the team,
whether this person represents an in-house information department
or is retained as an outside consultant. This individual will
assess the facility's readiness for FFDM, in network and other
information infrastructure terms. FFDM-related picture archiving
and communications system (PACS) connectivity, data transfer, and
information storage should also be evaluated by the information
specialist.
The finance department should be represented by a team member
who will assess the capital outlay and ongoing operational and
maintenance costs required for conversion from SFM to FFDM. The
finance team members should also study the effect of the new
technology on revenues, since the ultimate financial success (or
failure) of FFDM will be dependent on the balance between income
and costs. Likewise, a team member representing the office staff
should apply his or her expertise to evaluating the impact of FFDM
on patient parking and waiting areas, report turnaround and flow,
and patient scheduling.
If the institution is large, a team member from the
organization's purchasing department should assist by carefully
reviewing proposed contract terms that assure the desired
performance outcomes. Other consultants to the evaluation team can
include, as appropriate, manufacturer's representatives from the
vendors of the FFDM systems under consideration, of laser printers,
of PACS, and of other technologies, as needed.
The assembled team should begin its investigation by clarifying
the facility's reasons for pursuing FFDM. A list of potential
problems (changes) created by SFM technology should be created, as
well as a list of benefits expected from FFDM. These lists should
concentrate on limitations and advantages in clinical, regulatory,
technical, financial, and operational areas. When complete, these
lists will provide a structure that allows the team to fill in the
necessary blanks while investigating the new technology. Sources of
information that may prove useful during this phase of data
collection are the Web sites of vendors and academic departments,
manufacturers' representatives, meetings and educational courses
offered by professional societies, and articles in the medical
literature.
COST JUSTIFICATION
Given the challenges faced by mammography providers,
profitability is never guaranteed, and many imaging facilities that
offer SFM find themselves hovering on the edge of financial losses.
This, of course, may lead such institutions to wonder how they
could possibly afford to institute FFDM service, given the fact
that the initial per-unit cost of equipment acquisition may exceed
that for SFM by a factor of three or four. An objective review of
the financial aspects of FFDM ownership, conducted so as to
minimize the influence of simple desire for the new technology, is
in order.
Contacting FFDM vendors is helpful in beginning this financial
analysis. They can provide valuable assistance because the
development and marketing of FFDM systems have allowed them to
gather information from other buyers that may not be available
elsewhere. They are, of course, in the business of promoting FFDM
sales, but given their bias, their expertise is useful. By applying
critical thinking to the evaluation of a vendor's claims, the buyer
can verify the assumptions of the manufacturer's analysis. This
step, in which the buyer adjusts the vendor's projections to
produce realistic estimates based on its own experience, can
clarify the financial outcome that the individual practice should
expect.
It is certainly encouraging to note that FFDM reimbursement
under the Medicare program can be 50% greater than SFM
reimbursement, although there may be regional variations in total
reimbursement levels. The financial feasibility of FFDM should not
be assessed on this basis alone, however.
TABLE. FFDM SAMPLE FINANCIAL ANALYSIS
|
| SFM REVENUE | COSTS |
| Cases/year | 8,000* | Film Cost/year @ $5/case | $40,000 |
| Medicare Reimbursement | $95 | FFDM Capital Cost | $400,000 |
| % Operating Capacity | 85% | CAD Capital Cost | $150,000 |
| S/F Annual Gross Revenue | $646,000 | Years Amortization | 5 |
| | Cost FFDM/year | $80,000 |
| | Cost CAD/year | $30,000 |
| |
| FFDM & CAD REVENUE | ANNUAL NET SFM REVENUE |
| FFDM Multiplier | 1.5 | S/F Annual Gross Revenue | $646,000 |
| FFDM Gross Annual Income | $969,000 | Film Cost/year @ $5/case | 40,000 |
| CAD/case | $15 | Net SFM Revenue | $606,000 |
| CAD Gross Annual Income | $102,000 | |
| FFDM + CAD Annual Income | $1,071,000 | |
| |
| NET REVENUE FROM FFDM VS.
SFM |
| *Cases/hour | 4 | Annual Revenue, FFDM + CAD | $1,071,000 |
| Hours/day | 8 | Annual Net Revenue, SFM | 606,000 |
| Cases/day | 32 | Capital Cost (FFDM + CAD), Annualized for 5 Years | 110,000 |
| Days/year | 250 | | __________ |
| | Annual Increase in Net Revenue for FFDM
Conversion | $355,000 |
| | 5-year Cumulative Increase in Net Revenue for FFDM
Conversion | $1,775,000 |
| |
| Adapted from material provided by Hologic, Inc.
Reprinted from Seminars in Breast Disease, Vol 6(2) Pizzutiello RJ.
Practical and Logistical Aspects of Implementing Full-Field
Digital Mammography , 49-57, 2003, with permission from
Elsevier. |
The table above shows the type of financial analysis that an
FFDM vendor might provide to a potential buyer. This analysis
assumes that 8,000 mammograms per year will be performed (at a rate
of four cases per hour for 250 working days per year). An average
Medicare reimbursement of $95 per SFM case is also assumed. Given
these assumptions, the gross revenue per year for SFM would be
$646,000. For the same set of assumptions, the gross revenue for
FFDM with computer-aided diagnosis (CAD) would be $1.07 million;
this calculation is based on a 1.5 relative reimbursement factor
for FFDM and an additional $15 reimbursement per case for CAD.
Cost analysis involves other factors, of course. The table's
example assumes a cost of $5 per SFM patient for film, reducing
revenue by $40,000. The capital costs are presumed to be $150,000
for CAD and $400,000 for FFDM, with all equipment amortized over a
period of 5 years (at $110,000 per year).
Determining roughly how much the facility in this example could
earn by converting from SFM to FFDM involves subtracting the net
annual revenue for SFM from the annual income from FFDM with CAD.
This yields a difference of $465,000 per year, from which the
annual amortized equipment cost of $110,000 is subtracted to yield
$355,000 in additional net income. After 5 years, the initial
equipment cost for FFDM plus CAD will have been recovered fully. An
additional profit of $1.78 million will have been generated.
Naturally, there are several other factors that do not appear in
a relatively simple analysis of this kind. Nonetheless, they should
be part of a thorough financial evaluation of FFDM. These factors
include the mix of screening versus diagnostic studies,
reimbursement levels from payors outside Medicare (and the relevant
payor mix), debt-service costs, and the expenses associated with
equipment service (contractual or otherwise) for SFM and FFDM.
Likewise, potential buyers should consider the savings to be gained
by eliminating wet film processing, along with the associated costs
of capital equipment, supplies, equipment service, and chemical use
and disposal. The more a vendor's analysis can be expanded to suit
a facility's situation, the more likely it is to predict the
financial consequences of implementing FFDM accurately.
It also should be noted that the foregoing example is very
conservative in estimating patient throughput at four cases per
hour. A 1995 workflow study1 found FFDM to take an
average of 8.5 minutes per patient and SFM to take an average of
12.9 minutes for the same mix of screening and diagnostic
procedures. This represents a 34% reduction in examination time for
FFDM.
CONCLUSION
It is possible that today's financial climate may cause existing
SFM systems to be perceived as too expensive to maintain. An SFM
unit is definitely among the least costly pieces of capital
equipment in an imaging center, but the reimbursements that accrue
to its use are low. The cost of delivering mammography services
using SFM may be large by comparison, especially when radiologist
and staff productivity levels are taken into account. Any
consideration of FFDM acquisition should evaluate the time spent,
using SFM, for the technologist to obtain the images, for the
support staff to file and keep track of the resulting films, and
for the radiologist to interpret the study. In addition to the film
and processing costs already analyzed, the wet processor needed for
SFM requires space (which may be more or less valuable according to
the facility's age and location, but should always be a component
of cost analysis). FFDM, evaluated in this light, will probably be
expected to increase productivity, possibly reduce expenses, or
both.
The imaging facility that fails to form an assessment team to
consider a new technology is at the same disadvantage as the center
or practice that does not bother to conduct a detailed
investigation of a proposed purchase. While happy accidents
sometimes occur (where the right technology is acquired for the
wrong reasons), more commonly mistakes and disappointments happen
that could have been avoided. In pursuing change, radiology
providers can obtain poor results if they fail to consider the full
impact of that change across the enterprise. Likewise, mistakes can
be made when a mammography service is expected to adopt solutions
that work in general radiology, with no adaptation for the unique
circumstances of mammography. Personal relationships, internal
political considerations, external pressures, and capital costs are
also likely to drive bad decisions if they are considered in
isolation. The optimal change process, instead, relies on a fully
informed multidisciplinary team that conducts a thorough technology
assessment.
Robert J. Pizzutiello, Jr, MS, is president, Upstate Medical Physics, Victor, NY.
References:
- Rothenberg LN, Haus AG. Physicists in mammography - a historical perspective. Med Phys. 1995;22:1923-1924.